MIST | Milestone Pharmaceuticals Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.7250 - 1.9050
52 Week Range	1.1200 - 3.52
Beta	2.70
Implied Volatility	220.64%
IV Rank	100.00%
Day's Volume	608,906
Average Volume	253,398
Shares Outstanding	53,327,900
Market Cap	99,189,894
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-05-09

Valuation
Profitability
Growth
Health
P/E Ratio	-2.33
Forward P/E Ratio	N/A
EPS	-0.80
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	47
Country	Canada
Website	MIST

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

MIST's peers: BYSI, DMAC, GALT, IKT, MCRB, ONCY, SCPH, LIFE, XFOR, GRTX, TERN, DAWN, HOOK, SPRO, BOLT, CHRS, GRCL, NLTX, GLUE, NAMS, IVA, CGEM, CMPX, PRTA, XCUR

*Chart delayed

Analyzing fundamentals for MIST we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see MIST Fundamentals page.

Watching at MIST technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on MIST Technicals page.